FDA label 0eaf4670-1a9d-487c-9559-5c0bbb73a91d

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
0eaf4670-1a9d-487c-9559-5c0bbb73a91d
SPL ID
0eaf4670-1a9d-487c-9559-5c0bbb73a91d
Version
1
Effective date
2011-03-16
Source export date
2026-10-12
Source partition
3
Source file
https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/f40eac55ff4c5d55c3d8bbc5766ea7e21e4196960cfb4703b96a406b491c0cd5/drug-label-0003-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 01:34:09

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Do not exceed recommended dosage. If nervousness, dizziness, or sleeplessness occurs, patients should discontinue use and consult their physician. Patients should consult their physician if they have heart disease, high blood pressure, thyroid disease, diabetes or difficulty in urination due to enlargement of the prostate gland. Dexchlorpheniramine maleate should be used with caution in patients with stenosing peptic ulcer, pyloroduodenal obstruction, or bladder neck obstruction. Due to its mild atropine-like action, dexchlorpheniramine maleate should be used cautiously in patients with bronchial asthma. Patients should not take this product, unless directed by their physician, if they have a breathing problem such as emphysema or chronic bronchitis, or if they have glaucoma. Antihistamines may diminish mental alertness.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS Dexchloroheniramine Maleate Slight to moderate drowsiness may occur and is the most frequent side effect. Other possible side effects of antihistamines include: General: urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chilis, dryness of mouth, nose and throat; Cardiovascular: hypotension, headache, palpitation, tachycardia, extrasystoles; Hematologic: hemolytic anemia, thrombocy1openia, agranulocytosis; CNS: sedation, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, hysteria, neuritis, convulsion; Gastrointestinal: epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation; Genitourinary: urinary frequency, difficult urination, urinary retention, early menses; Respiratory: thickening of bronchial secretions, tightness of chest, wheezing and nasal stuffiness Pseudoephedrine HCI Pseudoephedrine may cause mild central nervous system stimulation, especially in those patients who are hypersensitive to sympathomimetic drugs. Nervousness, excitability, restlessness, dizziness, weakness and insomnia may also occur. Headache and drowsiness have also been reported. Large doses may cause lightheadedness, nausea and/or vomiting. Sympathomimetic drugs have also been associated with certain untoward reactions including fear, anxiety, tenseness, restlessness, tremor, weakness, pallor, respiratory difficulty, dysuria, insomnia, hallucination, convulsion, CNS depression, arrhythmias and cardiovascular collapse with hypotension.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.